TG Therapeutics, Inc. (TGTX)
64.48
-0.08
(-0.12%)
USD |
NASDAQ |
Nov 13, 16:00
64.48
0.00 (0.00%)
After-Hours: 19:59
TG Therapeutics Enterprise Value : 10.01B for Nov. 12, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 12, 2026 | 10.01B |
| November 11, 2026 | 10.19B |
| November 10, 2026 | 9.963B |
| November 09, 2026 | 9.830B |
| November 06, 2026 | 9.293B |
| November 05, 2026 | 9.014B |
| November 04, 2026 | 9.566B |
| November 03, 2026 | 9.433B |
| November 02, 2026 | 9.312B |
| October 30, 2026 | 9.498B |
| October 29, 2026 | 9.029B |
| October 28, 2026 | 8.926B |
| October 27, 2026 | 8.781B |
| October 26, 2026 | 8.532B |
| October 23, 2026 | 8.438B |
| October 22, 2026 | 8.285B |
| October 21, 2026 | 8.291B |
| October 20, 2026 | 8.492B |
| October 19, 2026 | 8.307B |
| October 16, 2026 | 8.408B |
| October 15, 2026 | 8.715B |
| October 14, 2026 | 8.468B |
| October 13, 2026 | 8.464B |
| October 12, 2026 | 8.604B |
| October 09, 2026 | 8.619B |
| Date | Value |
|---|---|
| October 08, 2026 | 8.313B |
| October 07, 2026 | 8.254B |
| October 06, 2026 | 8.139B |
| October 05, 2026 | 8.399B |
| October 02, 2026 | 8.456B |
| October 01, 2026 | 8.355B |
| September 30, 2026 | 8.681B |
| September 29, 2026 | 8.804B |
| September 28, 2026 | 8.804B |
| September 25, 2026 | 8.993B |
| September 24, 2026 | 9.007B |
| September 23, 2026 | 8.775B |
| September 22, 2026 | 9.098B |
| September 21, 2026 | 8.952B |
| September 18, 2026 | 8.908B |
| September 17, 2026 | 8.846B |
| September 16, 2026 | 8.752B |
| September 15, 2026 | 8.321B |
| September 14, 2026 | 8.468B |
| September 11, 2026 | 8.452B |
| September 10, 2026 | 8.681B |
| September 09, 2026 | 8.568B |
| September 08, 2026 | 8.735B |
| September 04, 2026 | 8.772B |
| September 03, 2026 | 8.883B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Amneal Pharmaceuticals, Inc. | 10.78B |
| Vertex Pharmaceuticals, Inc. | 137.73B |
| Regeneron Pharmaceuticals, Inc. | 91.75B |
| SELLAS Life Sciences Group, Inc. | 1.484B |
| Travere Therapeutics, Inc. | 5.077B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 55.46M |
| Revenue (Quarterly) | 259.94M |
| Total Expenses (Quarterly) | 204.47M |
| EPS Diluted (Quarterly) | 0.3557 |
| Gross Profit Margin (Quarterly) | 83.81% |
| Profit Margin (Quarterly) | 21.34% |
| Earnings Yield | 1.04% |
| Operating Earnings Yield | 1.89% |
| Normalized Earnings Yield | 1.118 |